MA32458B1 - Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer - Google Patents

Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer

Info

Publication number
MA32458B1
MA32458B1 MA33496A MA33496A MA32458B1 MA 32458 B1 MA32458 B1 MA 32458B1 MA 33496 A MA33496 A MA 33496A MA 33496 A MA33496 A MA 33496A MA 32458 B1 MA32458 B1 MA 32458B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
combination
aminoheteroaryl compound
met antagonist
Prior art date
Application number
MA33496A
Other languages
Arabic (ar)
English (en)
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MA32458B1 publication Critical patent/MA32458B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur une composition renfermant un antagoniste d'anticorps dirigé contre c-Met et un composé aminohétéroaryle, en particulier en tant que médicament. La présente invention concerne également une composition pharmaceutique contenant ledit anticorps anti-c-Met et ledit composé aminohétéroaryle en tant que produits de combinaison pour une utilisation simultanée, séparée ou séquentielle. L'invention porte sur l'utilisation de la composition de l'invention pour le traitement d'un cancer chez un mammifère.
MA33496A 2008-07-08 2011-01-07 Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer MA32458B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12959808P 2008-07-08 2008-07-08
EP20080305387 EP2143441A1 (fr) 2008-07-08 2008-07-08 Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
PCT/EP2009/058709 WO2010003992A1 (fr) 2008-07-08 2009-07-08 Combinaison d'un antagoniste de c-met et d'un composé aminohétéroaryle pour le traitement d'un cancer

Publications (1)

Publication Number Publication Date
MA32458B1 true MA32458B1 (fr) 2011-07-03

Family

ID=39924962

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33496A MA32458B1 (fr) 2008-07-08 2011-01-07 Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer

Country Status (15)

Country Link
US (3) US8623359B2 (fr)
EP (2) EP2143441A1 (fr)
JP (1) JP5677949B2 (fr)
KR (1) KR20110043548A (fr)
CN (1) CN102083465B (fr)
AU (1) AU2009268040B2 (fr)
BR (1) BRPI0915446A2 (fr)
CA (1) CA2730110C (fr)
ES (1) ES2668970T3 (fr)
GE (1) GEP20135829B (fr)
IL (1) IL210404A (fr)
MA (1) MA32458B1 (fr)
MX (1) MX2011000255A (fr)
RU (1) RU2526171C2 (fr)
WO (1) WO2010003992A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (fr) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
KR20140045440A (ko) * 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
CN103204844A (zh) * 2012-01-17 2013-07-17 上海艾力斯医药科技有限公司 氨基杂芳基化合物及其制备方法与应用
ES2927651T3 (es) * 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
KR102306656B1 (ko) * 2013-07-03 2021-09-29 삼성전자주식회사 항 c-Met 항체를 이용하는 암의 병용 치료
SG11201600754PA (en) * 2013-08-14 2016-02-26 Qiagen Mansfield Inc Compositions and methods for multimodal analysis of cmet nucleic acids
WO2015031614A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de la cmet soluble
WO2015031626A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de cmet soluble
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
WO2016053610A1 (fr) * 2014-10-03 2016-04-07 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR741285A (fr) 1932-08-22 1933-02-08
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20050233960A1 (en) * 2003-12-11 2005-10-20 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
RU2398777C2 (ru) * 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
PL1786785T3 (pl) * 2004-08-26 2010-08-31 Pfizer Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
SI1959955T1 (sl) * 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
GB0621607D0 (en) * 2006-10-31 2006-12-06 Chroma Therapeutics Ltd Inhibitors of c-Met
EP2014681A1 (fr) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
EP2635602B1 (fr) * 2010-11-03 2016-09-07 Argen-X Nv Anticorps anti c-met

Also Published As

Publication number Publication date
WO2010003992A1 (fr) 2010-01-14
RU2011103125A (ru) 2012-08-20
EP2315601A1 (fr) 2011-05-04
US9011865B2 (en) 2015-04-21
BRPI0915446A2 (pt) 2015-11-10
GEP20135829B (en) 2013-05-27
ES2668970T3 (es) 2018-05-23
US9375425B2 (en) 2016-06-28
US20140186356A1 (en) 2014-07-03
US8623359B2 (en) 2014-01-07
US20110117098A1 (en) 2011-05-19
MX2011000255A (es) 2014-04-16
AU2009268040B2 (en) 2014-11-20
CA2730110A1 (fr) 2010-01-14
JP2011527313A (ja) 2011-10-27
US20150250780A1 (en) 2015-09-10
JP5677949B2 (ja) 2015-02-25
AU2009268040A1 (en) 2010-01-14
EP2315601B1 (fr) 2018-02-14
IL210404A0 (en) 2011-03-31
KR20110043548A (ko) 2011-04-27
RU2526171C2 (ru) 2014-08-20
IL210404A (en) 2017-06-29
CN102083465A (zh) 2011-06-01
EP2143441A1 (fr) 2010-01-13
CN102083465B (zh) 2015-05-27
WO2010003992A8 (fr) 2011-02-10
CA2730110C (fr) 2018-10-02

Similar Documents

Publication Publication Date Title
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
MY160703A (en) Crystalline forms of (r) -5- [3-chloro-4-(2,3-dihydroxy) - benz [z] ylidene] -2- ([z]-propylimino) -3-0-tolyl-thiazolidin-4-one
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
MA29615B1 (fr) Preparations et methodes pour le diagnostic et le traitement d'une tumeur
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MY155317A (en) Benzene sulfonamide thiazole and oxazole compounds
SV2011003786A (es) Compuestos quimicos 251
MA30655B1 (fr) Composes organiques.
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA38534A1 (fr) Compositions synergiques comprenant le (2s)-2-ethoxy-3-(4-(2-(2-methyl-5-(4-methylsulfanylphenyl)pyrrol-1-yl)ethoxy)phenyl)propanoate et des agents, par ex. Inhibiteurs de dipeptidyl peptidase-4, biguanide et/ou statines pour une utilisation dans la dyslipidémie
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
MA34067B1 (fr) Composés à base de complexes de fe(iii) pour le traitement et la prévention des carences en fer et des anémies dues à une carence en fer
MA26964A1 (fr) Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase.
GEP20094680B (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MX2010005013A (es) Composiciones intranasales.
MA37742B1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MA34554B1 (fr) Combinaisons pharmaceutiques
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA32275B1 (fr) Preparations orales et injectables de composes de tetracycline
MA29145B1 (fr) Préparations pharmaceutiques pour le traitement de la cellulite